Related Experiment Video

Updated: Jul 23, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

MIB2 promotes the progression of non-small cell lung cancer by regulating cell cycle control pathways

Yiru Kong1,2, Jing Li1, Xiaohua Liang1

  • 1¹Department of Oncology, Huashan Hospital Fudan University, 12 Middle Urumqi Road, Shanghai, 200000, China.

Genes & Genomics
|July 12, 2023
PubMed
Abstract

Insights

MIB2 is upregulated in non-small cell lung cancer (NSCLC) and drives tumor growth by affecting cell cycle control. Reducing MIB2 inhibits NSCLC progression, proliferation, and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Understanding the molecular mechanisms of lung cancer is crucial for identifying new therapeutic targets.
  • The role of MIB2 in lung cancer pathogenesis requires further investigation.

Purpose of the Study:

  • To investigate the role of MIB2 in the development and progression of non-small cell lung cancer (NSCLC).
  • To explore MIB2 as a potential therapeutic target for NSCLC.

Main Methods:

  • Comparative analysis of MIB2 expression in lung cancer versus normal tissues using public databases and clinical samples.
  • Quantitative real-time PCR (Rt-PCR) and Western blot to assess MIB2 expression.
  • Cell proliferation assays (CCK8, clone formation), migration (Transwell), and invasion assays to evaluate MIB2's functional impact.
  • Analysis of cell cycle control pathway proteins to elucidate MIB2's mechanism of action.

Main Results:

  • MIB2 expression is significantly upregulated in NSCLC tissues compared to adjacent normal tissues.
  • Downregulation of MIB2 expression inhibits proliferation, metastasis, and invasion of NSCLC cell lines.
  • Knockdown of MIB2 leads to decreased expression of key cell cycle regulators, including cyclins and cyclin-dependent kinases (CDK2, CDK4, cyclinB1).

Conclusions:

  • MIB2 functions as a driver oncogene in NSCLC tumorigenesis.
  • MIB2 regulates NSCLC progression through the modulation of cell cycle control pathways.
  • Targeting MIB2 may represent a viable therapeutic strategy for NSCLC.
Keywords:
Cell cycleMIB2NSCLCProliferation

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K